FindTrial
Sign In

TO KNOW VISUAL RESULTS OF IMPLANTABLE CONTACT LENSES WITH CENTAL HOLE DESIGN IN PATIENTS WITH VERY HIGH SHORT SIGHTEDNESS

EVALUATION OF CLINICAL OUTCOME OF THE VISIAN IMPLANTABLE COLLAMER LENS WITH CENTRAL FLOW TECHNOLOGY (V4C ICL) IN MYOPIA

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2014/05/004640
Enrollment
50
Registered
2014-05-29
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- HEALTHY INDIVIDUAL WITH SHORT SIGHTS OPTING FOR REFRACTIVE PROCEDURE

Interventions

Intervention1: IMPLANTING VISIAN ICL V4C SERIES WITH CENTRA FLOW TECNOLOGY: IMPLANTING IMPLANTABLE COLLAMER LENS WITH CENTRA FLOW TECHNOLOGY IN FRONT OF NATURAL CRYSTALLINE LENS IN PATIENTS WITH MYOPI

Sponsors

NETRADHAMA SUPERSPECIALITY EYE HOSPITAl
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Myopia in the range (from0.50 diopter [D] to 18.00 D), 2. Age older than 20 years, 3. Corrected distance visual acuity (CDVA) of 20/40 or better, 4. Stable refraction, 5. Clear central cornea.

Exclusion criteria

Exclusion criteria: 1. Previous corneal refractive surgery, 2. Anterior chamber depth (acd) from the endothe-lium of less than 2.8 mm, 3. corneal endothelial cell density less than 2000 cell/mm2 4. Mesopic pupil larger than 7.0 mm, 5. history of glaucoma or ocular in�ammation, pre-existing corneal disease, 6. endothelial count less than 2500 cells/mm 7. Cataract, history of glaucoma, amblyopia, retinal detachment ,diabetic retinopathy, macular degeneration, neuro-ophthalmic disease, and a history of ocular inflammation.

Design outcomes

Primary

MeasureTime frame
TO KNOW THE VISUAL OUTCOME EFFICACY AND PREDECTIBILITY POST ICL IMPLANTATIONTimepoint: PATIENTS ARE FOLLOWED UP AND DETAILED EVALUATION DONE ON POST OP DAY 1 ,2 WEEKS AND 1 month and 3 MONTHS—

Secondary

MeasureTime frame
TO KNOW THE INTRA OCULAR PRESSURE VARIATION, ENDOTHELIAL CELL DENSITY AND ANY INDUCE ABERRATIONS WITH THE NEW V4C SERIES ICLTimepoint: PATIENTS ARE FOLLOWED UP AND DETAILED EVALUATION DONE ON POST OP DAY 1 ,2 WEEKS 1 month AND 3 MONTHS—

Countries

India

Contacts

Public ContactDR SRI GANESH

NETHRADHAMA SUPERSPECIALITY EYE HOSPITAL

drshobhabs@gmail.com9886972296

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026